Adults With Growth Hormone Deficiency Using Biosimilar Somatropin (Omnitrope®) Long-Term Face No Higher Risk Of Glucose Metabolism Disorders
Reading Time: 4 minutes Objective The purpose is to assess how treatment with recombinant human growth hormone (rhGH; Omnitrope®) impacts the possibility of developing diabetes mellitus in adults diagnosed with growth hormone deficiency (GHD) by analyzing data from the PATRO Adults post-marketing surveillance study. Methods All adult patients over 30 years who have received more than or equal to one dose of Omnitrope® in... Read more »